Tom Chu

1.2k total citations
21 papers, 872 citations indexed

About

Tom Chu is a scholar working on Epidemiology, Molecular Biology and Hepatology. According to data from OpenAlex, Tom Chu has authored 21 papers receiving a total of 872 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Epidemiology, 7 papers in Molecular Biology and 6 papers in Hepatology. Recurrent topics in Tom Chu's work include Influenza Virus Research Studies (8 papers), Receptor Mechanisms and Signaling (6 papers) and Hepatitis C virus research (6 papers). Tom Chu is often cited by papers focused on Influenza Virus Research Studies (8 papers), Receptor Mechanisms and Signaling (6 papers) and Hepatitis C virus research (6 papers). Tom Chu collaborates with scholars based in United States, Switzerland and United Kingdom. Tom Chu's co-authors include Craig R. Rayner, Uri Lopatin, Nancy S. Shulman, Edward Gane, Brett Ritchie, Patrick F. Smith, Peter Angus, Stuart K. Roberts, David Ipe and Eric Prinssen and has published in prestigious journals such as The Lancet, Nature Medicine and Gastroenterology.

In The Last Decade

Tom Chu

19 papers receiving 851 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Tom Chu United States	14	583	399	161	157	117	21	872
Jens Kort United States	17	717 1.2×	905 2.3×	407 2.5×	129 0.8×	108 0.9×	61	1.4k
Shingo Nakamoto Japan	23	844 1.4×	1.0k 2.6×	222 1.4×	245 1.6×	86 0.7×	107	1.6k
Esperance Schaefer United States	20	518 0.9×	398 1.0×	269 1.7×	209 1.3×	61 0.5×	45	1.1k
Nora A. Fierro Mexico	18	359 0.6×	411 1.0×	156 1.0×	142 0.9×	49 0.4×	51	867
Michael Cooreman United States	13	417 0.7×	364 0.9×	72 0.4×	254 1.6×	22 0.2×	23	910
Domenico Criscuolo Italy	15	495 0.8×	452 1.1×	52 0.3×	88 0.6×	32 0.3×	42	918
Helena Allende Spain	22	970 1.7×	1.0k 2.6×	76 0.5×	116 0.7×	49 0.4×	60	1.4k
Asem Elfert Egypt	17	409 0.7×	379 0.9×	110 0.7×	144 0.9×	50 0.4×	61	852
W. Sandborn United States	17	646 1.1×	66 0.2×	43 0.3×	134 0.9×	95 0.8×	73	1.5k
Yasuo Takekoshi Japan	17	202 0.3×	114 0.3×	57 0.4×	167 1.1×	70 0.6×	29	919

Countries citing papers authored by Tom Chu

Since Specialization

Citations

This map shows the geographic impact of Tom Chu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tom Chu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tom Chu more than expected).

Fields of papers citing papers by Tom Chu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tom Chu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tom Chu. The network helps show where Tom Chu may publish in the future.

Co-authorship network of co-authors of Tom Chu

This figure shows the co-authorship network connecting the top 25 collaborators of Tom Chu. A scholar is included among the top collaborators of Tom Chu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tom Chu. Tom Chu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Zabka, Tanja S., Michael Lawton, Tom Chu, et al.. (2025). Biomarkers of Drug‐Induced Kidney Injury: Use in Clinical Trials and Recent Examples of Impact on Drug Development. Clinical Pharmacology & Therapeutics. 119(3). 608–617.

Tang, Fei, Rebecca Kunder, Tom Chu, et al.. (2023). First‐in‐human phase 1 trial evaluating safety, pharmacokinetics, and pharmacodynamics of NLRP3 inflammasome inhibitor, GDC‐2394, in healthy volunteers. Clinical and Translational Science. 16(9). 1653–1666. 37 indexed citations

Metz, Martin, Gordon Sussman, Rémi Gagnon, et al.. (2021). Fenebrutinib in H1 antihistamine-refractory chronic spontaneous urticaria: a randomized phase 2 trial. Nature Medicine. 27(11). 1961–1969. 94 indexed citations

Oh, Jiwon, Stanley Cohen, David Isenberg, et al.. (2021). The Safety of Fenebrutinib in a Large Population of Patients With Diverse Autoimmune Indications Supports Investigation in Multiple Sclerosis (MS) (4564). Neurology. 96(15_supplement). 9 indexed citations

Lim, Jeremy J., Juan Pablo Horcajada, Allen Nguyen, et al.. (2021). A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial of the Monoclonal Antibody MHAA4549A in Patients With Acute Uncomplicated Influenza A Infection. Open Forum Infectious Diseases. 9(2). ofab630–ofab630. 10 indexed citations

Lim, Jeremy J., Nicholas Lewin‐Koh, Tom Chu, et al.. (2020). 167. A Phase 1b, Randomized, Double-blind, Placebo-controlled, Multiple-ascending Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of DSTA4637S in Patients with staphylococcus Aureus Bacteremia Receiving Standard-of-care Antibiotics. Open Forum Infectious Diseases. 7(Supplement_1). S213–S213. 6 indexed citations

Lim, Jeremy J., Anna Nilsson, Michael Silverman, et al.. (2020). A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial of MHAA4549A, a Monoclonal Antibody, plus Oseltamivir in Patients Hospitalized with Severe Influenza A Virus Infection. Antimicrobial Agents and Chemotherapy. 64(7). 29 indexed citations

D’Angelo, June Ann, et al.. (2020). IFN-α Suppresses Myeloid Cytokine Production, Impairing IL-12 Production and the Ability to Support T-Cell Proliferation. The Journal of Infectious Diseases. 222(1). 148–157. 8 indexed citations

Jensen, Donald M., Michael J. Brunda, Robert C. Elston, et al.. (2015). Interferon‐free regimens containing setrobuvir for patients with genotype 1 chronic hepatitis C: a randomized, multicenter study. Liver International. 36(4). 505–514. 14 indexed citations

10.

Tan, Anthony T., Long Hoàng, Daniel J. Chin, et al.. (2013). Reduction of HBV replication prolongs the early immunological response to IFNα therapy. Journal of Hepatology. 60(1). 54–61. 62 indexed citations

11.

Niet, A. de, Louis Jansen, Hans L. Zaaijer, et al.. (2013). Experimental Hbsag/Anti-Hbs Complex Assay for Prediction of Hbeag Loss in Chronic Hepatitis B Patients Treated with Pegylated Interferon and Adefovir. Antiviral Therapy. 19(3). 259–267. 10 indexed citations

12.

Chu, Tom, Rohit Kulkarni, Edward Gane, et al.. (2012). Effect of IL28B Genotype on Early Viral Kinetics During Interferon-Free Treatment of Patients With Chronic Hepatitis C. Gastroenterology. 142(4). 790–795. 72 indexed citations

13.

Toovey, Stephen, Eric Prinssen, Craig R. Rayner, et al.. (2012). Post-Marketing Assessment of Neuropsychiatric Adverse Events in Influenza Patients Treated with Oseltamivir: An Updated Review. Advances in Therapy. 29(10). 826–848. 31 indexed citations

14.

Gane, Edward, Stuart K. Roberts, Peter Angus, et al.. (2010). Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial. The Lancet. 376(9751). 1467–1475. 240 indexed citations

15.

Asselah, Tarik, Laurent Essioux, Patrick Marcellin, et al.. (2010). 1180 A CHROMOSOME 19 SNP (RS12979860) PREDICTS OUTCOME (EVR/SVR) IN HCV PATIENTS TREATED WITH INTERFERON, INDEPENDENT OF PEGYLATION OR RIBAVIRIN. Journal of Hepatology. 52. S456–S456. 14 indexed citations

16.

Lindemann, Lothar, Helmut Jacobsen, Frédéric Knoflach, et al.. (2009). In vitro pharmacological selectivity profile of oseltamivir prodrug (Tamiflu®) and active metabolite. European Journal of Pharmacology. 628(1-3). 6–10. 26 indexed citations

17.

Hoffmann, Gerhard, Christoph Funk, Stephen Fowler, et al.. (2009). Nonclinical Pharmacokinetics of Oseltamivir and Oseltamivir Carboxylate in the Central Nervous System. Antimicrobial Agents and Chemotherapy. 53(11). 4753–4761. 28 indexed citations

18.

Toovey, Stephen, Craig R. Rayner, Eric Prinssen, et al.. (2008). Assessment of Neuropsychiatric Adverse Events in Influenza Patients Treated with Oseltamivir. Drug Safety. 31(12). 1097–1114.

19.

Toovey, Stephen, Craig R. Rayner, Eric Prinssen, et al.. (2008). Assessment of Neuropsychiatric Adverse Events in Influenza Patients Treated with Oseltamivir. Drug Safety. 31(12). 1097–1114. 126 indexed citations

20.

Schentag, Jerome J., George Hill, Tom Chu, & Craig R. Rayner. (2007). Similarity in Pharmacokinetics of Oseltamivir and Oseltamivir Carboxylate in Japanese and Caucasian Subjects. The Journal of Clinical Pharmacology. 47(6). 689–696. 38 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact